Study of antiphospholipid antibodies in patients treated with antiepileptic drugs

Neurologia

Volumn 16, Issue 1, 2001, Pages 7-10

  Pardo, A ^a   Gonzalez Porque P ^a   Gobernado, J M ^a   Jimenez Escrig A ^a   Lousa, M ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Anticardiolipin antibodies; Anticonvulsivant drugs; Antiphospholipid antibodies; Lupus anticoagulant; Thrombosis

Indexed keywords

ANTICONVULSIVE AGENT; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; ASSAY; BLOOD CLOTTING TEST; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PREVALENCE; SERODIAGNOSIS; THROMBOCYTOPENIA; THROMBOSIS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTICARDIOLIPIN; ANTICONVULSANTS; EPILEPSY; FEMALE; HUMANS; IMMUNOGLOBULIN M; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0035098010     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Annotation. Antiphospholipid antibodies
2. Laboratory identification of the lupus anticoagulant
3. Immunological and clinical importance of antiphospholipid antibodies
4. Significance of the lupus anticoagulant
5. Primary antiphospholipid syndrome
6. Thrombosis, recurrent fetal loss, and thrombocytopenia: Predictive value of the anticardiolipin antibody assay
7. Antiphospholipid antibodies: Anticardiolipin and lupus anticoagulant in systemic lupus erythematous (SLE) and in non-SLE disorders. Prevalence and clinical significance
8. The role of leukocyte-generate reactive metabolites in the pathogenesis of idiosyncratic drug reactions
9. Study of antiphospholipid antibodies in a patient with Sneddon's syndrome and her family
10. Lupus anticoagulant and Sneddon's syndrome
11. The relationship between lupus anticoagulant and antibodies to phospholipid
12. A clinical study of the lupus anticoagulant
13. The use of the dilute russell viper venom time for the diagnosis of the lupus anticoagulants
14. Thrombosis, abortion, cerebral disease and lupus anticoagulant
15. A hemorrhage disorder caused by circulating anticoagulant in patients with disseminated lupus erythematous
16. Acquired inhibitors of blood coagulation
17. Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia
18. Recurrent thromboembolic and stroke risk in patients with neurological events and antiphospholipid antibodies
19. Neurological disease associated with antiphospholipid antibodies
20. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematous, lupus-like disease and the primary antiphospholipid syndrome
21. The primary antiphospholipid syndrome: Major clinical and serological features
22. Anti-phospholipid antibodies
23. Anticardiolipin antibodies and lupus anticoagulants comprise separate subgroups with different phospholipid binding characteristics
24. Lupus anticoagulant and increased thrombin generation in patients with systemic lupus erythematous
25. Increased immunoglobulin binding to cerebral endothelium in patient with antiphospholipid antibodies
26. The anticardiolipin syndrome
27. Anticardiolipin antibodies: Isotype distribution and phospholipid specifity
28. The membrane actions of anesthetic and tranquilizers
29. Heterogeneity of laboratory test results for antiphospholipid antibodies in patients treated with chlorpromazine and other phenothiazines
30. Chlorpromazine-induced anticardiolipin antibodies and lupus anticoagulant: Absence of thrombosis